Pinto Shelly 4

What Happened
Shelly Pinto, SVP, Finance and Chief Accounting Officer of ALX Oncology Holdings, was granted a derivative award of 192,000 shares (an option/award) on January 26, 2026. The reported acquisition price is $0.00, indicating this is a compensation grant rather than an open-market purchase. This is not a sale; grants are routine executive compensation and do not by themselves signal a buy or sell decision.

Key Details

• Transaction date: 2026-01-26 (Form 4 filed 2026-01-28) — filing appears timely.
• Transaction type/code: Award/Grant (derivative), reported as acquisition at $0.00.
• Number of shares/options: 192,000 granted.
• Vesting: Per footnote, shares/options vest in 48 equal monthly installments beginning February 26, 2026.
• Shares owned after transaction: Not specified in the provided filing details.
• No 10b5-1 plan, tax withholding, or cashless exercise indicated in the filing.

Context
This filing documents an equity compensation grant (a derivative award) rather than a market purchase or sale. Such grants are common for executives and are structured to align incentives over time via vesting schedules; they do not reflect an immediate change in market exposure because the shares vest gradually. Retail investors should view this as routine compensation disclosure rather than a direct trading signal.